Sopherion Therapeutics Report issue

For profit Phase 3
Founded: East Brunswick NJ United States (2001)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2006
NCT00294996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1